Gene

Neurofibromatosis

Biology

Chromatin remodeling

Ezrin

Signal transduction

Cancer research

Merlin (protein)

SMARCB1

Radixin

Genetics

Neurofibromin 1

Moesin

Cytoskeleton

Tumor suppressor gene

Cell

Carcinogenesis

Suppressor

PI3K/AKT/mTOR pathway

Gene expression

Neurofibromatosis type 2

International Journal of Molecular Sciences

Neurofibromatosis (NF) is a neurocutaneous syndrome characterized by the development of tumors of the central or peripheral nervous system including the brain, spinal cord, organs, skin, and bones. There are three types of NF: NF1 accounting for 96% of all cases, NF2 in 3%, and schwannomatosis (SWN) in &lt;1%. The NF1 gene is located on chromosome 17q11.2, which encodes for a tumor suppressor protein, neurofibromin, that functions as a negative regulator of Ras/MAPK and PI3K/mTOR signaling pathways. The NF2 gene is identified on chromosome 22q12, which encodes for merlin, a tumor suppressor protein related to ezrin-radixin-moesin that modulates the activity of PI3K/AKT, Raf/MEK/ERK, and mTOR signaling pathways. In contrast, molecular insights on the different forms of SWN remain unclear. Inactivating mutations in the tumor suppressor genes SMARCB1 and LZTR1 are considered responsible for a majority of cases. Recently, treatment strategies to target specific genetic or molecular events involved in their tumorigenesis are developed. This study discusses molecular pathways and related targeted therapies for NF1, NF2, and SWN and reviews recent clinical trials which involve NF patients.

Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis